Login to Your Account

Clinic Roundup

Friday, July 6, 2012
• Biotie Therapies Oyj, of Turku, Finland, said it completed enrollment in its Phase IIb trial testing tozadenant in Parkinson's disease and expects top-line data to be available around the end of the year. The 420-patient study is designed to determine the efficacy of the selective adenosine 2A receptor inhibitor in reducing the mean number of hours per day patients spend in the "off" state.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription